Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Nanobiotix S.A
NBTX | US
4.81
USD0.08
1.69%
NBTX | US
About Nanobiotix S.A
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
4.81
Open
4.85
High
4.86
Low
4.81
Nanobiotix S.A. a clinical-stage biotechnology focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3 a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma head and neck cancers liver cancers prostate cancer pancreatic cancer esophageal cancer rectal cancer and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China South Korea Singapore and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris France.
View LessNBTX | US
Risk
57.0
Sharpe
-0.42
Luna's Score
43/100
Recommendation
Sell
Luna says (NBTX | US)
What's Working
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
28.6%1 month
57.0%3 months
63.7%6 months
71.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
48.31
Price to book
65.02
Debt to equity
-2.04
Debt to assets
0.51
Ent. to EBITDA
-2.45
Ent. to rev.
5.22
PEG
-
Other Fundamentals
EBITDA
-22.30M
MarketCap
229.20M
MarketCap(USD)
229.20M
Div. yield
-
Op. margin
-253.32
Erngs. growth
-
Rev. growth
182.10
Ret. on equity
-198.69
Short ratio
2.52
Short perc.
0.08
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.68
Range1M
1.18
Range3M
1.46
Volumes: Market Activity
Rel. volume
0.28
Price X volume
10.24K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.45 | - | Cheaper |
| Ent. to Revenue | 5.22 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 65.02 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 63.72 | - | Par |
| Debt to Equity | -2.04 | -1.23 | Cheaper |
| Debt to Assets | 0.51 | 0.25 | Expensive |
| Market Cap | 229.20M | - | Emerging |
